GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ABUS · Mar 31, 2024

Arbutus Biopharma Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001447028-24-000038General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

6.20% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1259.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-77.09% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1263.90% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1005.42% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

131.46% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20246/7 normalizedLevel 3 Mar 31, 20256/7 normalizedLevel 3 Jun 30, 20256/7 normalizedLevel 3 Sep 30, 20256/7 normalizedLevel 3 Dec 31, 20257/7 normalizedLevel 3 Mar 31, 20266/6 normalizedLevel 3 Jun 30, 20266/6 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 5.56%
Current: 6.20%
Delta: 0.64%

Cash Generation Decreased

Previous: -473.71%
Current: -1259.46%
Delta: -785.75%

Growth Decreased

Previous: -53.51%
Current: -77.09%
Delta: -23.58%

Profitability Decreased

Previous: -430.53%
Current: -1263.90%
Delta: -833.37%

R And D Intensity Increased

Previous: 406.26%
Current: 1005.42%
Delta: 599.16%

Sbc Intensity Increased

Previous: 51.27%
Current: 131.46%
Delta: 80.19%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ABUS Fundamental State →Transitioned To · ABUS Fundamental State →Transitioned To · ABUS CAPEX_INTENSITY_INCREASED →Transitioned To · ABUS CASH_GENERATION_DECREASED →Transitioned To · ABUS GROWTH_DECREASED →Transitioned To · ABUS PROFITABILITY_DECREASED →Transitioned To · ABUS R_AND_D_INTENSITY_INCREASED →Transitioned To · ABUS SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.